Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma

Jessica Lubahn, Sonja I. Berndt, Carol H. Jin, Aleksandra Klim, Jason Luly, William S. Wu, Sarah Isaacs, Kathleen Wiley, William B Isaacs, Brian K. Suarez, Richard B. Hayes, Adam S. Kibel

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Because of the dramatically different clinical course of aggressive and indolent prostate carcinoma (PCa), markers that distinguish between these phenotypes are of critical importance. Apoptosis is an important protective mechanism for unrestrained cellular growth and metastasis. Therefore, dysfunction in this pathway is a key step in cancer progression. As such, genetic variants in apoptosis genes are potential markers of aggressive PCa. Recent work in breast carcinoma has implicated the histidine variant of CASP8 D302H (rs1045485) as a protective risk allele. METHODS. We tested the hypothesis that the H variant was protective for aggressive PCa in a pooled analysis of 796 aggressive cases and 2,060 controls. RESULTS. The H allele was associated with a reduced risk of aggressive PCa (ORper allele = 0.67, 95% CI: 0.54-0.83, Ptrend = 0.0003). The results were similar for European-Americans (ORper allele = 0.68; 95% CI: 0.54-0.86) and African-Americans (ORper allele = 0.61; 95% CI: 0.34-1.10). We further determined from the full series of 1,160 cases and 1,166 controls in the Prostate, Lung, Colorectal, Ovarian (PLCO) population that the protective effect of the H allele tended to be limited to high-grade and advanced PCa (all cases ORper allele = 0.94; 95% CI: 0.79-1.11; localized, low-grade disease ORper allele = 0.98; 95% CI: 0.79-1.23; and aggressive disease ORper allele = 0.73; 95% CI: 0.50-1.07). CONCLUSION. These results suggest that histidine variant of CASP8 D302H is a protective allele for aggressive PCa with potential utility for identification of patients at differential risk for this clinically significant phenotype.

Original languageEnglish (US)
Pages (from-to)646-653
Number of pages8
JournalProstate
Volume70
Issue number6
DOIs
StatePublished - May 1 2010

Fingerprint

Prostate
Alleles
Carcinoma
Histidine
Apoptosis
Phenotype
African Americans
Breast Neoplasms
Neoplasm Metastasis
Lung
Growth
Population
Genes

Keywords

  • Apoptosis
  • Cancer susceptibility
  • Metastatic disease
  • Prostate carcinoma
  • Risk assessment

ASJC Scopus subject areas

  • Urology
  • Oncology
  • Medicine(all)

Cite this

Lubahn, J., Berndt, S. I., Jin, C. H., Klim, A., Luly, J., Wu, W. S., ... Kibel, A. S. (2010). Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. Prostate, 70(6), 646-653. https://doi.org/10.1002/pros.21098

Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. / Lubahn, Jessica; Berndt, Sonja I.; Jin, Carol H.; Klim, Aleksandra; Luly, Jason; Wu, William S.; Isaacs, Sarah; Wiley, Kathleen; Isaacs, William B; Suarez, Brian K.; Hayes, Richard B.; Kibel, Adam S.

In: Prostate, Vol. 70, No. 6, 01.05.2010, p. 646-653.

Research output: Contribution to journalArticle

Lubahn, J, Berndt, SI, Jin, CH, Klim, A, Luly, J, Wu, WS, Isaacs, S, Wiley, K, Isaacs, WB, Suarez, BK, Hayes, RB & Kibel, AS 2010, 'Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma', Prostate, vol. 70, no. 6, pp. 646-653. https://doi.org/10.1002/pros.21098
Lubahn J, Berndt SI, Jin CH, Klim A, Luly J, Wu WS et al. Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. Prostate. 2010 May 1;70(6):646-653. https://doi.org/10.1002/pros.21098
Lubahn, Jessica ; Berndt, Sonja I. ; Jin, Carol H. ; Klim, Aleksandra ; Luly, Jason ; Wu, William S. ; Isaacs, Sarah ; Wiley, Kathleen ; Isaacs, William B ; Suarez, Brian K. ; Hayes, Richard B. ; Kibel, Adam S. / Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. In: Prostate. 2010 ; Vol. 70, No. 6. pp. 646-653.
@article{933230a135aa4a9fae067857ee27e0ee,
title = "Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma",
abstract = "BACKGROUND. Because of the dramatically different clinical course of aggressive and indolent prostate carcinoma (PCa), markers that distinguish between these phenotypes are of critical importance. Apoptosis is an important protective mechanism for unrestrained cellular growth and metastasis. Therefore, dysfunction in this pathway is a key step in cancer progression. As such, genetic variants in apoptosis genes are potential markers of aggressive PCa. Recent work in breast carcinoma has implicated the histidine variant of CASP8 D302H (rs1045485) as a protective risk allele. METHODS. We tested the hypothesis that the H variant was protective for aggressive PCa in a pooled analysis of 796 aggressive cases and 2,060 controls. RESULTS. The H allele was associated with a reduced risk of aggressive PCa (ORper allele = 0.67, 95{\%} CI: 0.54-0.83, Ptrend = 0.0003). The results were similar for European-Americans (ORper allele = 0.68; 95{\%} CI: 0.54-0.86) and African-Americans (ORper allele = 0.61; 95{\%} CI: 0.34-1.10). We further determined from the full series of 1,160 cases and 1,166 controls in the Prostate, Lung, Colorectal, Ovarian (PLCO) population that the protective effect of the H allele tended to be limited to high-grade and advanced PCa (all cases ORper allele = 0.94; 95{\%} CI: 0.79-1.11; localized, low-grade disease ORper allele = 0.98; 95{\%} CI: 0.79-1.23; and aggressive disease ORper allele = 0.73; 95{\%} CI: 0.50-1.07). CONCLUSION. These results suggest that histidine variant of CASP8 D302H is a protective allele for aggressive PCa with potential utility for identification of patients at differential risk for this clinically significant phenotype.",
keywords = "Apoptosis, Cancer susceptibility, Metastatic disease, Prostate carcinoma, Risk assessment",
author = "Jessica Lubahn and Berndt, {Sonja I.} and Jin, {Carol H.} and Aleksandra Klim and Jason Luly and Wu, {William S.} and Sarah Isaacs and Kathleen Wiley and Isaacs, {William B} and Suarez, {Brian K.} and Hayes, {Richard B.} and Kibel, {Adam S.}",
year = "2010",
month = "5",
day = "1",
doi = "10.1002/pros.21098",
language = "English (US)",
volume = "70",
pages = "646--653",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma

AU - Lubahn, Jessica

AU - Berndt, Sonja I.

AU - Jin, Carol H.

AU - Klim, Aleksandra

AU - Luly, Jason

AU - Wu, William S.

AU - Isaacs, Sarah

AU - Wiley, Kathleen

AU - Isaacs, William B

AU - Suarez, Brian K.

AU - Hayes, Richard B.

AU - Kibel, Adam S.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - BACKGROUND. Because of the dramatically different clinical course of aggressive and indolent prostate carcinoma (PCa), markers that distinguish between these phenotypes are of critical importance. Apoptosis is an important protective mechanism for unrestrained cellular growth and metastasis. Therefore, dysfunction in this pathway is a key step in cancer progression. As such, genetic variants in apoptosis genes are potential markers of aggressive PCa. Recent work in breast carcinoma has implicated the histidine variant of CASP8 D302H (rs1045485) as a protective risk allele. METHODS. We tested the hypothesis that the H variant was protective for aggressive PCa in a pooled analysis of 796 aggressive cases and 2,060 controls. RESULTS. The H allele was associated with a reduced risk of aggressive PCa (ORper allele = 0.67, 95% CI: 0.54-0.83, Ptrend = 0.0003). The results were similar for European-Americans (ORper allele = 0.68; 95% CI: 0.54-0.86) and African-Americans (ORper allele = 0.61; 95% CI: 0.34-1.10). We further determined from the full series of 1,160 cases and 1,166 controls in the Prostate, Lung, Colorectal, Ovarian (PLCO) population that the protective effect of the H allele tended to be limited to high-grade and advanced PCa (all cases ORper allele = 0.94; 95% CI: 0.79-1.11; localized, low-grade disease ORper allele = 0.98; 95% CI: 0.79-1.23; and aggressive disease ORper allele = 0.73; 95% CI: 0.50-1.07). CONCLUSION. These results suggest that histidine variant of CASP8 D302H is a protective allele for aggressive PCa with potential utility for identification of patients at differential risk for this clinically significant phenotype.

AB - BACKGROUND. Because of the dramatically different clinical course of aggressive and indolent prostate carcinoma (PCa), markers that distinguish between these phenotypes are of critical importance. Apoptosis is an important protective mechanism for unrestrained cellular growth and metastasis. Therefore, dysfunction in this pathway is a key step in cancer progression. As such, genetic variants in apoptosis genes are potential markers of aggressive PCa. Recent work in breast carcinoma has implicated the histidine variant of CASP8 D302H (rs1045485) as a protective risk allele. METHODS. We tested the hypothesis that the H variant was protective for aggressive PCa in a pooled analysis of 796 aggressive cases and 2,060 controls. RESULTS. The H allele was associated with a reduced risk of aggressive PCa (ORper allele = 0.67, 95% CI: 0.54-0.83, Ptrend = 0.0003). The results were similar for European-Americans (ORper allele = 0.68; 95% CI: 0.54-0.86) and African-Americans (ORper allele = 0.61; 95% CI: 0.34-1.10). We further determined from the full series of 1,160 cases and 1,166 controls in the Prostate, Lung, Colorectal, Ovarian (PLCO) population that the protective effect of the H allele tended to be limited to high-grade and advanced PCa (all cases ORper allele = 0.94; 95% CI: 0.79-1.11; localized, low-grade disease ORper allele = 0.98; 95% CI: 0.79-1.23; and aggressive disease ORper allele = 0.73; 95% CI: 0.50-1.07). CONCLUSION. These results suggest that histidine variant of CASP8 D302H is a protective allele for aggressive PCa with potential utility for identification of patients at differential risk for this clinically significant phenotype.

KW - Apoptosis

KW - Cancer susceptibility

KW - Metastatic disease

KW - Prostate carcinoma

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=77950887652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950887652&partnerID=8YFLogxK

U2 - 10.1002/pros.21098

DO - 10.1002/pros.21098

M3 - Article

VL - 70

SP - 646

EP - 653

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 6

ER -